Detalhe da pesquisa
1.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38832972
2.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
3.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood
; 141(14): 1685-1690, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608320
4.
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.
Amyloid
; 31(2): 86-94, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38206120
5.
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Clin Lymphoma Myeloma Leuk
; 24(3): 194-202, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052709
6.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38062124
7.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 42(1): 26-37, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37753960
8.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Hematology
; 29(1): 2320006, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407192
9.
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 41(2): 696-715, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38110653
10.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38302221
11.
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
Cancers (Basel)
; 15(18)2023 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37760637
12.
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
Bone Marrow Transplant
; 58(11): 1182-1188, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543712
13.
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Adv Ther
; 40(5): 2412-2425, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36961654
14.
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics.
Invest Radiol
; 58(10): 754-765, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222527
15.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol
; 9(11): e810-e821, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328040
16.
Deteriorated executive functions in patients with successful surgery for pituitary adenomas compared with other chronically ill patients.
J Int Neuropsychol Soc
; 17(2): 369-75, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205414
17.
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Cancers (Basel)
; 13(19)2021 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638344
18.
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Blood Cancer J
; 11(1): 1, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414374
19.
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Leukemia
; 35(4): 1134-1144, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32694619
20.
Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma.
Blood Cancer J
; 10(1): 2, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31915365